Cargando…
P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
Autores principales: | Jaeger, U., Broome, C., Go, R., Patriarca, A., Roeth, A., Chang, Q., Weedin, N., Adams, P., Cahir-McFarland, E., Kroon, H.-A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429239/ http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55 |
Ejemplares similares
-
The anx/anx Mouse – A Valuable Resource in Anorexia Nervosa Research
por: Nilsson, Ida A. K.
Publicado: (2019) -
Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates
por: Grover, Anita, et al.
Publicado: (2023) -
Role of Complement in Autoimmune Hemolytic Anemia
por: Berentsen, Sigbjørn
Publicado: (2015) -
Senate Bill No. 1552
Publicado: (1896) -
Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia
por: Liu, Bainan, et al.
Publicado: (2013)